Patient guide · nr-axSpA · English
Non-radiographic axial spondyloarthritis
Understanding the diagnosis, treatment and everyday care
In this guide
1. What the name means
The name is long; the central idea is simpler. Axial spondyloarthritis, or axSpA, is an inflammatory disease that mainly affects the sacroiliac joints and spine. The sacroiliac joints connect the sacrum, at the base of the spine, to the pelvis. Other joints, tendon attachments, eyes, skin or bowel may also be involved. [1] [2]
What does “non-radiographic” mean?
Ordinary X-rays do not show sacroiliac-joint changes that meet the established radiographic threshold. They may be normal or show changes below that threshold, including limited or uncertain findings. MRI can still show inflammation or structural changes. “Non-radiographic” does not mean that every scan is normal. [1] [2] [4]
Is this early ankylosing spondylitis?
Sometimes, but not always. Some people later develop definite X-ray changes and are then described as having radiographic axSpA, also called ankylosing spondylitis (AS). Others remain non-radiographic over many years. Neither diagnosis means that spinal fusion is inevitable. [1] [3]
Author’s note on terminology
In older records or everyday clinical conversation, you may hear “ankylosing spondylitis” used more broadly. In this guide, axSpA is the umbrella term; nr-axSpA and radiographic axSpA/AS are distinguished when the X-ray category matters. Ask which findings the name in your own record refers to.
Symptoms worth describing
Tell your clinician about when symptoms began, night pain, stiffness, buttock pain, changes with movement or rest, and swollen joints or painful tendon attachments. Mention confirmed psoriasis, eye inflammation and bowel disease. These clues guide assessment; they are not a checklist for diagnosing yourself. [2]
2. How the diagnosis is put together
No single blood test, scan or online quiz can establish nr-axSpA. A rheumatologist combines your history, examination, test results and possible alternative explanations. Women as well as men can have axial SpA. Current age is not the same as age when symptoms began. [2] [7]
HLA-B27: a clue, not a verdict
HLA-B27 is an inherited marker associated with susceptibility. A positive result does not prove that you have the disease, and a negative result does not rule it out. It is not a measurement of how active inflammation is today. [2] [7]
CRP and ESR: useful, but not the whole picture
These blood tests can indicate inflammation in the body. They may be normal in axSpA. When elevated, the clinician must consider other possible causes. Normal results still contribute information; they should not simply be ignored. [2]
Why a dedicated MRI may be needed
A lumbar-spine MRI is not the same examination as an MRI designed to assess the sacroiliac joints. The appropriate study looks for both active inflammation and structural changes. Bring earlier images, not only reports, when they are available. [4] [19]
Why MRI can also mislead
Bone-marrow edema means a change in the fluid-sensitive signal inside bone. It can occur with inflammation, but also with physical loading or after childbirth. Its location and accompanying findings matter. Tell the team about pregnancy, delivery, training, injury and treatment exposure. [5] [19]
When the evidence does not agree
Ask what supports the diagnosis, what argues against it, and what the next assessment could resolve. Another pain source can coexist with axSpA. Uncertainty should lead to a clear review plan, not repeated scans solely to obtain a preferred answer. [6] [7]
3. Treatment: what each part is for
The aim is to control supported inflammation and help you sleep, move, work and participate in daily life. Treatment does not need to wait until X-rays become clearly abnormal. Agree on a practical goal, such as less night waking or being able to finish an ordinary workday. [6] [7]
Movement and rehabilitation
An individualized program can include mobility, strengthening, posture, breathing and aerobic exercise. Start from what you can manage and adjust it with a physiotherapist. Exercise complements medication; it is not a demand to push through severe new pain or a replacement for necessary inflammation control. [2] [7]
Anti-inflammatory pain medicines
NSAIDs, such as ibuprofen or naproxen, may reduce pain and stiffness. The clinician considers your stomach, kidney and cardiovascular risks, other medicines, and actual response. Do not add another oral NSAID without checking with your prescriber or pharmacist. A drug that is unsafe or intolerable should not be taken simply to complete a treatment “ladder.” [6] [15]
When targeted treatment is considered
If active inflammatory disease remains inadequately controlled, TNF- or IL-17-targeting biologics or a JAK inhibitor may be appropriate. Evidence of inflammation, previous treatment, risks and local approvals matter. In the United States, upadacitinib for adult nr-axSpA requires objective signs of inflammation and inadequate response or intolerance to a TNF blocker. A tablet is not automatically safer than an injection. [6] [7] [18]
Why one person receives a different medicine
Recurrent uveitis, significant psoriasis or inflammatory bowel disease can change the best choice. A treatment that helps the back may not be suitable for active bowel disease. Decisions may involve an ophthalmologist, dermatologist or gastroenterologist. [6] [7]
What is not an obligatory step
Methotrexate and similar conventional medicines are not established treatment for purely axial inflammation, though they may be used for another manifestation. Long-term oral steroids are not routine maintenance treatment for axial disease. Do not stop an existing prescription without clarifying why it was prescribed. [6]
4. Is treatment working—and what comes next?
Measure more than pain
Track pain, stiffness, fatigue, sleep and a specific activity separately. Your team may use ASDAS or other established questionnaires alongside examination and laboratory results. A personal 0–10 diary is useful for discussion; adding its numbers together does not create a validated disease score. [7]
Fatigue deserves its own plan
Fatigue can reflect inflammation, poor sleep, reduced physical capacity, another health problem or several contributors together. It deserves assessment even when blood tests improve. Addressing sleep or pain processing does not mean that the symptom is imagined. [8]
Persistent pain is not automatically drug failure
A medicine may control inflammation while another pain source remains. The team should also check missed doses, supply problems, side effects and whether there was an initial response. Changing treatment is different when a drug never helped than when it worked well and later lost effect. [6] [7]
Agree when the result will be reviewed
After a targeted medicine is started, a planned response assessment often takes place at about three to four months; problems may need attention much sooner. Ask when safety tests are due, who reviews them and how to report deterioration before the next appointment. [7]
Will the disease progress?
Some people develop definite X-ray changes; others do not during long follow-up. Remaining non-radiographic does not prove cure, and a changed X-ray category does not mean that the spine has fused. Population risk estimates cannot provide your exact future. [3]
Can treatment be reduced?
After sustained control, some people can try a clinician-agreed reduction. Lowering treatment is not the same as stopping it, and sudden withdrawal increases flare risk in studies. Agree on the exact regimen, review date and what to do if symptoms recur. Zero medication is not a requirement for success. [9]
5. Staying safe and planning everyday life
Before and during treatment
Ask which infection screening, vaccinations and monitoring apply to your medicine. Report a significant infection, new symptoms or an upcoming procedure promptly. Whether to hold a dose depends on the drug and the situation; obtain instructions rather than applying one rule to every medicine. [7] [16]
Make the plan workable
Discuss work breaks, commuting, exercise, travel and help with daily tasks. For injections or infusions, plan supply, storage and appointments with the pharmacy or team. Report access gaps without waiting until a medicine is labeled ineffective. Choose practical goals that matter to you.
Pregnancy and breastfeeding
Discuss plans before conception when possible. Some treatments can continue during pregnancy and breastfeeding; others need to be changed. Do not stop everything automatically, and seek prompt advice about an unplanned exposure. Disease control and the exact medicine both matter. [10]
An important NSAID warning
From 20 weeks of pregnancy, do not use NSAIDs on your own; they can affect fetal kidneys and amniotic fluid. Later pregnancy brings additional risks. Low-dose aspirin prescribed for an obstetric reason is a separate situation: do not stop it by applying this general warning. [11]
After delivery
Arrange your own follow-up and a medication plan compatible with the chosen feeding method. Tell the baby’s clinician exactly which immune-targeted medicines were used and when. Infant vaccine decisions depend on the medicine and exposure timing, not a blanket ban on all vaccines. [10]
Moving from pediatric to adult care
Carry forward the original diagnosis, previous images, medication responses and monitoring plan. Identify who will prescribe until the first adult appointment. Turning 18 or feeling well on treatment does not by itself establish that treatment is no longer needed. [13]
6. When to seek help—and how to prepare
Same-day assessment and urgent advice
A newly hot, painful, swollen joint needs same-day assessment, even without fever. Seek urgent advice about fever, suspected infection during immune-targeted treatment, or substantial new bowel symptoms. If your usual team is unavailable, use an urgent-care service. Severe illness or rapid deterioration requires emergency care. These examples are not a complete list. [7] [16] [17]
Before an ordinary visit
Bring your main question, a short symptom timeline, current medicines with doses and actual schedules, recent results and earlier images when available. Include over-the-counter products. Note what improved, what did not, and any delays in obtaining treatment. “Not sure” is a useful answer.
Leave with three answers
What is the next action? Who will arrange it and review the result? When is the next assessment, and how do I obtain earlier help? Write down the agreed plan rather than relying on memory.
Use the companion worksheet
The two-page visit worksheet is a place to organize your observations, not a test that labels you. Its personal ratings are not validated diagnostic criteria. Completing or downloading it does not notify a clinician or create a monitored messaging service.
A separate two-page worksheet accompanies this guide. Fill it in for your own clinical team; it is not a diagnostic test.
Sources and how to use this guide
The numbered references support the clinical explanations. The questions and everyday examples are editorial teaching aids, not diagnostic scores or instructions to prescribe. Most linked sources are in English.
- ASAS nomenclature consensus (2024)
- NICE NG65: spondyloarthritis diagnosis and management
- DESIR: sacroiliac radiographic progression over 10 years (2024)
- ASAS–SPARTAN: diagnostic sacroiliac MRI protocol (2024)
- MRI findings in healthy people, runners and postpartum women (2018)
- ASAS–EULAR management recommendations: 2022 update (2023)
- BSR targeted-treatment guideline for adult axSpA (2025)
- EULAR fatigue recommendations: 2023 recommendations (2024)
- C-OPTIMISE: treatment reduction versus withdrawal (2020)
- EULAR reproductive-health recommendations: 2024 update (2025)
- FDA: NSAIDs from 20 weeks of pregnancy
- NICE NG127: urgent neurological referral
- EULAR/PReS standards for transition to adult care (2017)
- NHS: uveitis and sudden loss of vision
- MedlinePlus: naproxen safety and interactions
- EULAR infection screening: 2022 recommendations (published 2023)
- NHS: septic arthritis—urgent assessment, including without fever
- DailyMed: Rinvoq—U.S. nr-axSpA indication and limitations
- ASAS: information for imaging referral and reporting (2024)
Educational information for adults and families, not an individual diagnosis or prescription. Your clinical team should agree any treatment change. This publication is not a clinic portal, emergency service or monitored messaging channel.
Keep completed worksheets within your clinical relationship. Do not post medical records, test results or identifying details in public comments or general correspondence with the author.
© 2026 Olga Goodman, MD · A RheumaView publication